Rational Development of LEA29Y (belatacept), a High-Affinity Variant of CTLA4-Ig with Potent Immunosuppressive PropertiesChristian P. Larsen, Robert Peach, Peter S. Linsley et al.|American Journal of Transplantation|2005Cited by 708
Persistent SARS-CoV-2–specific immune defects in kidney transplant recipients following third mRNA vaccine doseWilliam A. Werbel, Dorry L. Segev, Andrew H. Karaba et al.|American Journal of Transplantation|2023Cited by 19
Outcomes at 7 years post‐transplant in black vs nonblack kidney transplant recipients administered belatacept or cyclosporine in<scp>BENEFIT</scp>and<scp>BENEFIT</scp>‐<scp>EXT</scp>Sander Florman, Christian P. Larsen, Flavio Vincenti et al.|Clinical Transplantation|2018Cited by 9
Epitope Mapping of SARS-CoV-2 Spike Antibodies in Vaccinated Kidney Transplant Recipients Reveals Poor Spike Coverage Compared to Healthy ControlsAndrew H. Karaba, Aaron A.R. Tobian, William R. Morgenlander et al.|The Journal of Infectious Diseases|2023Cited by 5
Letter to the editor: “hook” (prozone) effect in sars‐cov‐2 anti‐spike binding antibody levels following vaccination, infection, or monoclonal antibody in solid organ transplant recipientsAura T. Abedon, William A. Werbel, Teresa Po‐Yu Chiang et al.|Clinical Transplantation|2023Cited by 1